SLT 0.00% 0.7¢ select exploration limited

hepatitis c is not a joke

  1. 22,691 Posts.
    http://www.epidemic.org/theFacts/essentials/theEpidemic.html

    And what about rapid diagnostics?

    Extracts from Announcements:

    3. HEPATITIS C:
    March 23, 2004: (HEP.C) Select Vaccines Limited (ASX:SLT) has entered into a materials transfer agreement (MTA) with a multi national biotech company to obtain materials that it plans to use to assist the acceleration of its Hepatitis C virus (HCV) rapid diagnostics development project.

    The MTA also provides that, upon successful development of proprietary information through use of the supplier company's material, then the supplier company will be able to exercise rights to licence or on-licence applications of such developments on commercial terms:
    http://stocknessmonster.com/news-item?S=SLT&E=ASX&N=217549

    April 13, 2004: Further MTA Signed for Hepatitis C Rapid Diagnostic Project.

    Further to its release of 23rd March 2004, Select Vaccines Limited (ASX:SLT) is pleased to announce that it has entered into an additional materials transfer agreement (MTA) with an established US-based diagnostics company to obtain access to that company’s diagnostic platform for use in Select’s Hepatitis C virus (HCV) rapid diagnostic development project.
    http://stocknessmonster.com/news-item?S=SLT&E=ASX&N=218342
    _____________

    "Much attention has recently been given to the increased incidence of the Hepatitis C virus infection and its potential to rival HIV in coming years as the disease afflicting millions of people throughout the world.

    Statistics highlight the fact that, currently, for every one person who dies from HIV, four people die from Hepatitis C related infections (source: US Centers for Disease Control and Prevention).

    Shareholders in SLT are already aware of the work being undertaken by the Company and its subsidiary project companies for the development of reliable, rapid diagnostic tests, including those targeting the Hepatitis C infection.

    SLT believes that successful development of a HCV (Hep.C Virus) diagnostic could have significant commercial potential through enabling a substantial improvement to the current regime for diagnosing and treating the disease".
    _______________________________________

    Gerry
    Readers, please do your own research and you decide if and when to buy, hold or sell any stocks. To visit archived posts, please use the Search button.



 
watchlist Created with Sketch. Add SLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.